(-)-(4aR,10aR)-3,4,4a,5,10,10a-hexahydro-6-methoxy-4-methyl-9-(methylthio)-2H-naphth[2,3-b]-1,4-oxazine hydrochloride | 103238-61-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: (-)-(4aR,10aR)-3,4,4a,5,10,10a-hexahydro-6-methoxy-4-methyl-9-(methylthio)-2H-naphth[2,3-b]-1,4-oxazine hydrochloride
• 英文别名: SDZ NVI-085；SDZ NVI-085 hydrochloride；Trans-3,4,4a,5,10,10a-hexahydro-6-methoxy-4-methyl-9-methylthio-2H-naphth[2,3-b]-1,4-oxazine hydrochloride；(-)-(4aR,10aR)-3,4,4a,5,10,10a-hexahydro-6-methoxy-4-methyl-9-methylthio-2H-naphth[2,3-b]-1,4-oxazine hydrochloride；(4aR,10aR)-6-methoxy-4-methyl-9-methylsulfanyl-2,3,4a,5,10,10a-hexahydrobenzo[g][1,4]benzoxazine;hydrochloride
• CAS: 103238-61-5
• 化学式: C₁₅H₂₁NO₂S*ClH
• 分子量: 315.864
• InChiKey: CWXFACKMNNJZSY-QMDUSEKHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.64
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  47
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  (4aR,10aR)-6-甲氧基-4-甲基-9-甲硫基-2,3,4a,5,10,10a-六氢萘并[2,3-b][1,4]恶嗪 、 盐酸 在 乙醚 作用下， 以 丙酮 为溶剂， 以(-)-(4aR,10aR)-3,4,4a,5,10,10a-hexahydro-6-methoxy-4-methyl-9-methylthio-2H-naphth[2,3-b]-1,4-oxazine hydrochloride is obtained (m.p. 237°-239°)的产率得到(-)-(4aR,10aR)-3,4,4a,5,10,10a-hexahydro-6-methoxy-4-methyl-9-(methylthio)-2H-naphth[2,3-b]-1,4-oxazine hydrochloride
  参考文献：
  名称：

  Naphthoxazines and their use as psychostimulating and antidepressant

  摘要：

  3,4,4a,5,10,10a-六氢-2H-萘[2,3-b]-1,4-噁唑因具有作为精神刺激剂和抗抑郁剂的用途。

  公开号：

  US04656167A1

文献信息

• Method for treating sleep-related breathing disorders
  申请人：Rao G. Srinivas

  公开号：US20060039866A1

  公开（公告）日：2006-02-23

  Compositions and methods for the treatment of sleep related breathing disorders are provided. Compositions include mirtazapine in combination with other active pharmaceutical ingredients, such as zonisamide, topiramate or modafinil. The treated sleep related breathing disorders include sleep apnea and sleep hypopnea. In some embodiments, the pharmaceutical compounds are used as adjuvant therapy with positive airway pressure (PAP) therapy, thereby lowering the pressure required to maintain airway patency during PAP therapy.

  本研究提供了用于治疗睡眠相关呼吸障碍的组合物和方法。组合物包括米氮平与其他活性药物成分（如唑尼沙胺、托吡酯或莫达非尼）的组合。治疗的睡眠相关呼吸障碍包括睡眠呼吸暂停和睡眠呼吸减弱。在某些实施方案中，药物化合物用作气道正压疗法的辅助疗法，从而降低气道正压疗法期间维持气道通畅所需的压力。
• Method for treating sleep-related breathing disorders with setiptiline
  申请人：Rao G. Srinivas

  公开号：US20060039867A1

  公开（公告）日：2006-02-23

  Compositions and methods for the treatment of sleep related breathing disorders are provided. Compositions include setiptiline in combination with other active pharmaceutical ingredients, such as zonisamide, topiramate or modafinil. The treated sleep related breathing disorders include sleep apnea and sleep hypopnea. In some embodiments, the pharmaceutical compounds are used as adjuvant therapy with positive airway pressure (PAP) therapy, thereby lowering the pressure required to maintain airway patency during PAP therapy.
• US4656167A
  申请人：——

  公开号：US4656167A

  公开（公告）日：1987-04-07
• [EN] METHOD FOR TREATING SLEEP RELATED BREATHING DISORDERS WITH SETIPTILINE<br/>[FR] METHODE DE TRAITEMENT DE TROUBLES RESPIRATOIRES LIES AU SOMMEIL A L'AIDE DE SETIPTILINE
  申请人：CYPRESS BIOSCIENCE INC

  公开号：WO2006023702A2

  公开（公告）日：2006-03-02

  Compositions and methods for the treatment of sleep related breathing disorders are provided. Compositions include setiptiline in combination with other active pharmaceutical ingredients, such as zonisamide, topiramate or modafinil. The treated sleep related breathing disorders include sleep apnea and sleep hypopnea. In some embodiments, the pharmaceutical compounds are used as adjuvant therapy with positive airway pressure (PAP) therapy, thereby lowering the pressure required to maintain airway patency during PAP therapy.